Fujifilm Healthcare Europe has introduced the AMULET SOPHINITY digital mammography system at the European Congress of Radiology 2024. The system is designed to offer high-resolution imaging while utilizing low-dose X-ray radiation, aimed at enhancing the accuracy and comfort of breast cancer diagnostics. Breast cancer is the leading cancer among women in Europe, and with cancer diagnoses expected to rise, the need for…
Innovate UK, the UK’s innovation agency, has awarded a significant grant of nearly £800,000 to a pioneering project, AI-VISION, aimed at advancing precision therapy in breast cancer treatment. This collaborative effort unites the expertise of cancer researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, with cosmology and astrophysics specialists from the University of Durham, and…
Lunit, a South Korean company that recently secured $150M, has announced its plan to acquire Volpara Health Technologies, an AI-enabled software company specializing in the early detection and prevention of cancer. The acquisition, which is expected to be completed by the second quarter of 2024, involves Lunit acquiring all Volpara shares at AUD 1.15 per share, amounting to a deal worth approximately…
GE HealthCare has announced the release of MyBreastAI Suite, a new AI-powered platform for mammography, designed to aid clinicians in detecting breast cancer. This platform integrates AI applications from iCAD, focusing on breast density assessment and enhancing the efficiency of mammography workflows. Addressing the challenges posed by the global rise in breast cancer cases, MyBreastAI Suite aims to streamline breast cancer detection.…
AI-enabled cancer diagnostics company Lunit, recently announced a financial boost with a $150M investment from its shareholders. The South Korean company, listed on the KOSDAQ, plans to invest these funds into new product development and strengthen its foothold in Western markets. The recent funding milestone is complemented by Lunit’s achievement in securing its third 510(k) clearance from the U.S. Food and Drug…
Mammogen, a precision diagnostics company, has recently completed the Clinical Laboratory Improvement Amendments (CLIA) validation for its genTRU-breast assay. This blood test is designed for the early detection of breast cancer and marks a significant step in the field of women’s health diagnostics. The foundation of Mammogen was inspired by a personal experience: the founder’s sister’s best friend, Katy, was diagnosed with…
Andira Pharmaceuticals, a Canadian health science firm, has recently announced significant progress in the treatment of breast cancer with its pioneering formula, XOXO4. The company’s flagship oncology candidate, XOXO4, has demonstrated remarkable efficacy in regressing human breast cancer tumors. Conducted at the University of British Columbia, the study highlighted that XOXO4, a cannabinoid formula applied topically, outperformed all eight FDA-approved breast cancer-specific…
Delphinus Medical Technologies, a pioneer in dense breast medical imaging, has secured $12M in growth capital from Trinity Capital. The funding will accelerate the adoption of their SoftVue 3D Whole Breast Tomography System, which enhances early breast cancer detection. The SoftVue system gained FDA approval in 2021 as an adjunct to digital mammography for screening asymptomatic women with dense breast tissue. Addressing…